Skip to main content
. Author manuscript; available in PMC: 2024 May 12.
Published in final edited form as: Trends Mol Med. 2023 Mar 17;29(5):406–418. doi: 10.1016/j.molmed.2023.02.005

Figure 4. Mechanism of mitapivat.

Figure 4.

Mitapivat, an oral allosteric pyruvate kinase activator, stabilizes and increases the activity of pyruvate kinase, thereby leading to increased intracellular red cell adenosine triphosphate (ATP), resulting in an improvement in anemia and patient-reported outcomes and a reduction in hemolysis. Abbreviation: ADP, adenosine diphosphate.